New Weight Loss Drug Retatrutide Delivers Stunning Results
Eli Lilly's new weight loss drug, retatrutide, shows promising results in recent trials. It may surpass the effectiveness of existing GLP-1 medications. Experts are discussing the potential timeline for FDA approval.
- ▪Retatrutide is designed to mimic three hormones that regulate hunger and fat burning.
- ▪The drug has shown remarkable test results, indicating it may be more effective than current GLP-1s.
- ▪Medical experts are analyzing the trial results and the likelihood of FDA approval.
6 outlets in our directory ran this story, first to last over 8 hours. Coverage spans 2 points on the political spectrum — 4 centre, 1 right.
- ▪ New obesity drug from Lilly delivers major weight loss — The Hill
- ▪ New Eli Lilly weight loss drug has dramatic effects in clinical trial — Washington Examiner
- ▪ A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says — TIME — Top
- ▪ Eli Lilly's next-generation weight loss injection posted record results in obesity trial — Quartz
- ▪ Eli Lilly says next-generation weight loss drug clears crucial obesity trial — US Top News and Analysis
NBC News — Top files mainly under news. We currently carry 565 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | TODAY.com |
| Canonical URL | https://www.today.com/video/new-weight-loss-drug-retatrutide-delivers-stunning-results-263708229582 |
| Publication time | Thu, 21 May 2026 12:04:51 GMT |
| Retrieval time | 2026-05-21T12:26:11.037Z |
| Last seen | 2026-05-21T12:26:11.037Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | aBS1rBimYei- · 6 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
CopiedRemarkable new test results by drugmaker Eli Lilly reveal that their latest weight loss drug, retatrutide, may be even more effective than the three popular GLP-1s currently available. The new drug is designed to mimic three hormones responsible for hunger regulation and fat burning. NBC’s medical contributor Dr. Natalie Azar breaks down the trial results and discusses how soon the new drug is likely to get FDA approval.May 21, 2026
Excerpt limited to ~120 words for fair-use compliance. The full article is at TODAY.com.
Discussion
0 commentsMore from TODAY.com
